RGEN insider trading
NasdaqGS HealthcareREPLIGEN CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About REPLIGEN CORP
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Company website: www.repligen.com
RGEN insider activity at a glance
FilingIQ has scored 783 insider transactions for RGEN since Mar 18, 2015. The most recent filing in our index is dated May 7, 2026.
Across the full history, 10 open-market purchases
and 367 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RGEN insider trades is 62.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RGEN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading RGEN
13F funds holding RGEN
Frequently asked
- How many insider trades does FilingIQ track for RGEN?
- FilingIQ tracks 783 Form 4 insider transactions for RGEN (REPLIGEN CORP), covering filings from Mar 18, 2015 onwards. 26 of those were filed in the last 90 days.
- Are RGEN insiders net buyers or net sellers?
- Across the full Form 4 history for RGEN, 10 transactions (1%) were open-market purchases and 367 (47%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RGEN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is RGEN in?
- REPLIGEN CORP (RGEN) is classified in the Healthcare sector, specifically Medical Instruments & Supplies, with a current market capitalisation of $7.56B.
Methodology & sources
Every RGEN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.